An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing cou...
Сохранить в:
| Опубликовано в:: | Biomédica |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Instituto Nacional de Salud
2013
|
| Предметы: | |
| Online-ссылка: | https://www.redalyc.org/articulo.oa?id=84329151010 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|